AIxMed and Biopticka Laboratoř Announce Strategic Collaboration to Advance AI-Powered Cytology in Europe

SANTA CLARA, Calif., Oct. 2, 2025 /PRNewswire/ -- AIxMed Inc., a leader in computational cytology and AI-powered diagnostics, and Biopticka Laboratoř s.r.o., the Czech Republic's leading private reference laboratory, today announced the signing of a Memorandum of Understanding (MOU) to integrate AIxURO^™ into their laboratory system. AIxURO^™ is AIxMed's proprietary AI-powered solution for urine cytology. AIxURO^™ is designed to support urine cytology workflows using The Paris System for Reporting Urinary Cytology (TPS), assisting in the detection of bladder cancer with enhanced diagnostic accuracy and efficiency.

Establishing a Flagship AI-Driven Cytology Laboratory

Under the MOU, Biopticka will be designated as a reference site for AIxMed in Europe, demonstrating the real-world application of AIxURO^™ to prospective partners and clients. Supported by AIxMed's partnerships with leading whole-slide imaging providers, the collaboration strengthens Biopticka as a flagship AI-driven cytology laboratory in the region. AIxMed will integrate into Biopticka's Laboratory Information System (LIS) and existing digital pathology infrastructure.

Expanding Beyond Urine Cytology

While the initial focus will be on bladder cancer detection, the Parties intend to jointly explore opportunities to expand into numerous high-impact cytology applications. These efforts include research collaborations, clinical validation studies, and co-authored publications aimed at advancing the role of AI in cytology.

Executive Quotes

"Our mission is to transform cancer diagnosis through computational cytology, and this partnership with Biopticka is a significant step toward that vision," said Samuel Chen, CEO and Cofounder of AIxMed. "Together, we will accelerate the adoption of advanced AI tools that improve diagnostic accuracy, efficiency, and ultimately patient outcomes."

"At Biopticka, we are committed to integrating the most advanced diagnostic technologies into clinical practice," said Michael Michal, statutory executive of Biopticka. "By adopting AIxMed's AIxURO^™ and collaborating on future innovations, we will enhance our services and deliver meaningful improvements in care for patients across the region."

About AIxMed Inc.

Founded in 2018 and headquartered in Santa Clara, California, AIxMed Inc. is pioneering computational cytology to transform cancer diagnosis and monitoring. Its flagship solution, AIxURO^™, leverages AI and The Paris System to assist in bladder cancer detection, offering improved accuracy and workflow efficiency. AIxURO^™ is currently a Research Use Only application. Learn more at www.aixmed.com.

About Biopticka Laboratoř s.r.o.

Based in Plzeň, Czech Republic, Biopticka Laboratoř s.r.o. is a distinguished reference laboratory specializing in pathology, histology, and molecular genetics. Known for delivering accurate and timely diagnostics, Biopticka partners with hospitals and clinicians across Central and Eastern Europe to provide high-quality, patient-centered diagnostic services.

SOURCE AIxMed, Inc.